Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | Chief Financial Officer | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.68 · Expires 2036-04-14 | Direct | 90,574 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 90,574 · Balance 90,574 F1: The stock option vests over a four-year period starting on April 15, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests over a four-year period starting on April 15, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 16, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,574 | $0.00 Strike: $67.68 | $0.00 |
DisclosureSEC source: 0001193125-26-159025 · ownership.xml · derivative · entry 1 DETORE JAMES M. · CIK 0001623981 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,574 Underlying: Common Stock · 90,574 shares Expires 2036-04-14 F1 · derivative.exercise_date: The stock option vests over a four-year period starting on April 15, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.